Onconic Therapeutics Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
04:32
Jan 06
Jan 06
Onconic drug sales fund cancer pipeline.
Onconic's self-developed GERD drug Zulcuvo is a fast-acting P-CAB that works within an hour versus older drugs' days-long lag, is already generating rapidly growing sales, and has export potential; that cash flow funds a dual PARP anticancer pipeline with broader indications and Keytruda combination potential, with May conference data as a catalyst for possible big pharma licensing.
HIGH
03:33
Jan 06
Jan 06
Onconic has GERD cash and cancer pipeline
Onconic's Jaqbo GERD drug has fast onset, self-developed export rights, and rapid sales growth; cash funds a dual synthetic-lethality cancer pipeline with May data and licensing potential.
MED
About Onconic Therapeutics Investor Commentary
Across the available history and selected sources, Buzzberg tracks Onconic Therapeutics across 1 sources: 2 bullish vs 0 bearish calls from 1 authors. Historical directional balance: 100% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 2 total trade ideas tracked. Latest voices: Noh Young-rae.